CTI BioPharma (LTS:0RLB) Asset Impairment Charge : €0.00 Mil (TTM As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is CTI BioPharma Asset Impairment Charge?

CTI BioPharma's Asset Impairment Charge for the three months ended in Mar. 2023 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2023 was €0.00 Mil.

CTI BioPharma Asset Impairment Charge Historical Data

The historical data trend for CTI BioPharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Asset Impairment Charge Chart

CTI BioPharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Asset Impairment Charge

Get a 7-Day Free Trial

CTI BioPharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

CTI BioPharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

CTI BioPharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

CTI BioPharma (LTS:0RLB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (LTS:0RLB) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121

Website

https://www.ctibiopharma.com

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (LTS:0RLB) Headlines

No Headlines